Company intelligence / Profile preview
Vortex Biotechnology
Tucson, Arizona, United Statesvortexbiotechnology.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Vortex Biotechnology is developing first-in-class small molecule drugs targeting novel cancer biology, with a lead oral stimulator of RNA degradation (VBT-34) in preclinical development for both hematological and solid tumors. The company also has experience with PIM1 inhibitors (e.g., SMI-4a). No clinical results have been published yet; programs are advancing toward clinical proof-of-concept[1][5].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
National Cancer InstituteMultiple NCI-designated Cancer Centers
Beyond the preview
Go deeper on Vortex Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vortex Biotechnology.